We are live on
!
Find out more
SFM
Sphera Funds Management Portfolio holdings
AUM
$767M
1-Year Est. Return
119.71%
This Fund
S&P 500
This Quarter
Est. Return
+6.27%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.02B
AUM Growth
-$45.6M
(-4.3%)
Cap. Flow
+$4.02M
Cap. Flow
% of AUM
0.39%
Top 10 Holdings %
Top 10 Hldgs %
45.69%
Holding
126
New
39
Increased
20
Reduced
28
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BTAI
BioXcel Therapeutics
BTAI
|
+$12.6M |
| 2 |
Johnson & Johnson
JNJ
|
+$11.8M |
| 3 |
Generac Holdings
GNRC
|
+$11M |
| 4 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$10.6M |
| 5 |
Eli Lilly
LLY
|
+$10.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$41.2M |
| 2 |
NVO
Novo Nordisk
NVO
|
+$26.2M |
| 3 |
Nice
NICE
|
+$14.2M |
| 4 |
Fiverr
FVRR
|
+$11.8M |
| 5 |
Q32 Bio
QTTB
|
+$10M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.97% |
| 2 | Miscellaneous | 15.76% |
| 3 | Technology | 5.67% |
| 4 | Consumer Discretionary | 2.57% |
| 5 | Industrials | 2.19% |
Similar funds
ISWM
ACP
NIM
ACM
CBT
SPIA
CNB
HI
Sphera Funds Management's Q3 2020 Portfolio in Review
As of Q3 2020, Sphera Funds Management held 126 positions worth $1.02B, down 4.3% from $1.06B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Sphera Funds Management's Q3 2020 filing shows 39 new, 20 increased, 28 reduced and 30 closed positions. Its largest new stake was BioXcel Therapeutics: 16,831 shares worth $11.7M. The largest sale was Bristol-Myers Squibb, an estimated $41.2M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Technology.
- Sphera Funds Management's largest Q3 2020 buy was BioXcel Therapeutics: 16,831 shares worth $11.7M.
- Sphera Funds Management added most to Johnson & Johnson in Q3 2020, an estimated $11.8M increase.
- Sphera Funds Management's biggest Q3 2020 reduction was Nice, cutting an estimated $14.2M.
- Sphera Funds Management fully exited Bristol-Myers Squibb in Q3 2020, selling an estimated $41.2M.
- Sphera Funds Management's ten largest holdings make up 46% of its $1.02B portfolio in Q3 2020.
- Sphera Funds Management opened 39 new positions and closed 30 in Q3 2020.
- Sphera Funds Management's portfolio value fell 4.3% quarter-over-quarter to $1.02B.
Based on Sphera Funds Management's 13F filing for Q3 2020, filed 12 Nov 2020.